SEC Form 4 · accession 0001209191-18-033068
CRESCENT BIOPHARMA, INC. · CBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John L. Magnani
Officer — SVP of Research, CSO · Director
Period of report
May 23, 2018
Accepted (ET)
May 24, 2018 · 5:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001253689
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 23, 2018 | M | 1,491 | $0.33 | A | 100,793 | D | |
| Common StockF1 | holding | — | — | — | 4,845 | I | By GlycoTech Corporation |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant to Purchase Common Stock (right to buy) | $0.33 | May 23, 2018 | M | 895 | D | Jul 3, 2008 | Jul 3, 2018 | Common Stock | 895 | 0 | D |
| Warrant to Purchase Common Stock (right to buy) | $0.33 | May 23, 2018 | M | 596 | D | Jan 16, 2009 | Jan 16, 2019 | Common Stock | 596 | 0 | D |
Explanation of responses
- F1These shares are held by GlycoTech Corporation, of which the reporting person is the sole stockholder.